This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Onyx Pharma Sinks; Genzyme Ticks Up

NEW YORK ( TheStreet) -- Shares of Onyx Pharmaceuticals (ONXX) tumbled on heavy volume late Thursday after the company delayed its new drug application for a proposed multiple myeloma treatment because of a Food and Drug Administration request for additional data on manufacturing the drug.

Onyx was originally planning to file the NDA by the end of this year, but it now anticipates the filing will occur in mid-2011 at the earliest. The company said it believes "minor variations" observed in the drug after a recent manufacturing run are related to equipment temperature variances, and that phase III trials for the drug remain on schedule.

"We are confident in the clinical and preclinical data package supporting the carfilzomib NDA and in our manufacturing strategy," said N. Anthony Coles, the company's president and CEO. "We believe that by providing this supportive data, we will strengthen our NDA package, thus enabling us to bring carfilzomib to patients with multiple myeloma as quickly as possible."

Onyx's stock was down 8.1% to $25.28 in extended trading with more than 1.2 million shares changing hands. Based on their regular session close at $27.50, the shares were already down about 11% so far in 2010, but had rallied somewhat since scraping a 52-week low of $19.54 on July 10.

Another biotech taking a dive after the close was Cytori Therapeutics (CYTX - Get Report), whose stock was off almost 13% to $4.65 on volume of around 63,000 after the company announced plans for a common stock offering. No word was given on the amount of shares the company is looking to sell.

Meantime, DragonWave (DRWI - Get Report) was gaining 6.6% to $7.10 on volume of more than 33,000 after the Canadian maker of packet microwave radio systems topped Wall Street expectations for its second-quarter earnings by a penny, and gave a bullish revenue outlook for revenue of $30 million in the third quarter.

Among the big caps, Micron Technology (MU - Get Report) was one of the most active issues in extended trading with volume of more than 4.4 million. The chip maker reported fiscal fourth-quarter earnings of $342 million, or 32 cents a share, on revenue of $2.49 billion, falling short of analyst estimates for a profit of 38 cents a share in the August-ended period on revenue of $2.65 billion. The stock was down 1.4% to $7.01 in late trades. Year-to-date, the shares are off more than 30%.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ONXX $0.00 0.00%
AA $13.49 -0.66%
CYTX $1.10 -1.80%
DRWI $0.72 -0.68%
MU $28.47 0.74%

Markets

DOW 18,050.88 +15.95 0.09%
S&P 500 2,107.69 +7.29 0.35%
NASDAQ 5,021.1010 +26.4990 0.53%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs